Association between occurrence of multiple white and flat elevated gastric lesions and oral proton pump inhibitor intake
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Multiple white and flat elevated lesions (MWFL) that develop from the gastric corpus to the fornix may be strongly associated with oral antacid intake. Therefore, this study aimed to determine the association between the occurrence of MWFL and oral proton pump inhibitor (PPI) intake and clarify the endoscopic and clinicopathological characteristics of MWFL. Methods: The study included 163 patients. The history of oral drug intake was collected, and serum gastrin levels and anti-Helicobacter pylori immunoglobulin G antibody titers were measured. Upper gastrointestinal endoscopy was performed. The primary study endpoint was the association between MWFL and oral PPI intake. Results: In the univariate analyses, MWFL were observed in 35 (49.3%) of 71 patients who received oral PPIs and 10 (10.9%) of 92 patients who did not receive oral PPIs. The occurrence of MWFL was significantly higher among patients who received PPIs than in those who did not (p<0.001). Moreover, the occurrence of MWFL was significantly higher in patients with hypergastrinemia (p=0.005). In the multivariate analyses, oral PPI intake was the only significant independent factor associated with the presence of MWFL (p=0.001; odds ratio, 5.78; 95% confidence interval, 2.06–16.2). Conclusions: Our findings suggest that oral PPI intake is associated with the presence of MWFL (UMINCTR 000030144).
Abstract
Background/Aims: Multiple white and flat elevated lesions (MWFL) that develop from the gastric corpus to the fornix may be strongly associated with oral antacid intake. Therefore, this study aimed to determine the association between the occurrence of MWFL and oral proton pump inhibitor (PPI) intake and clarify the endoscopic and clinicopathological characteristics of MWFL. Methods: The study included 163 patients. The history of oral drug intake was collected, and serum gastrin levels and anti-Helicobacter pylori immunoglobulin G antibody titers were measured. Upper gastrointestinal endoscopy was performed. The primary study endpoint was the association between MWFL and oral PPI intake. Results: In the univariate analyses, MWFL were observed in 35 (49.3%) of 71 patients who received oral PPIs and 10 (10.9%) of 92 patients who did not receive oral PPIs. The occurrence of MWFL was significantly higher among patients who received PPIs than in those who did not (p<0.001). Moreover, the occurrence of MWFL was significantly higher in patients with hypergastrinemia (p=0.005). In the multivariate analyses, oral PPI intake was the only significant independent factor associated with the presence of MWFL (p=0.001; odds ratio, 5.78; 95% confidence interval, 2.06–16.2). Conclusions: Our findings suggest that oral PPI intake is associated with the presence of MWFL (UMINCTR 000030144).
참고문헌 (20)
- Noffsinger A, "Fenoglio-Preiser's gastrointestinal pathology" (2017), Wolters Kluwer
- Kawaguchi M, "An investigation of white flat elevations in the gastric body", Gastroenterol Endosc, 49(Suppl 1), pp.958~ (2007)
- Kamada T, "New gastric lesion in the cardia induced by proton pump inhibitor treatment", Gastroenterology, 140(5 Suppl 1), pp.S719~ (2011)
- Hasegawa R, "Magnified endoscopic findings of multiple white flat lesions : a new subtype of gastric hyperplastic polyps in the stomach", Clin Endosc, 51, pp.558~562 (2018)
- Haruma K, "Problems of prolonged administration of PPI-occurrence of gastric polyps", Shokakinaika, 56, pp.190~193 (2013)
- Yamaoka R, "Novel endoscopic findings of multiple white flat lesions : a new subtype of hyperplastic polyps in the stomach", United European Gastroenterol J, 3(Suppl 1), pp.A386~ (2016)
- Ally MR, "Chronic proton pump inhibitor therapy associated with increased development of fundic gland polyps", Dig Dis Sci, 54, pp.2617~2622 (2009)
- Kim GH, "Proton pump inhibitor-related gastric mucosal changes", Gut Liver, 15, pp.646~652 (2021)
- Sugawara K, "Cases of gastric fundic gland polyps increasing in the size during the long-term therapy with proton pump inhibitor", Gastroenterol Endosc, 51, pp.1686~1691 (2009)
- Hongo M, "Incidence and risk factor of fundic gland polyp and hyperplastic polyp in long-term proton pump inhibitor therapy : a prospective study in Japan", J Gastroenterol, 45, pp.618~624 (2010)
- Takeda T, "Hemorrhagic polyps formed like fundic gland polyps during long-term proton pump inhibitor administration", Clin J Gastroenterol, 10, pp.478~484 (2017)
- Aoi K, "Fundic gland polyp with dysplasia developed during long-term proton pump inhibitor therapy, report of a case", Stomach Intest, 47, pp.1270~1274 (2012)
- Yao K, "The endoscopic diagnosis of early gastric cancer", Ann Gastroenterol, 26, pp.11~22 (2013)
- Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 3, pp.87~97 (1969)
- Shinozaki S, "The effect of proton pump inhibitors and vonoprazan on the development of ‘gastric mucosal redness’", Biomed Rep, 16, pp.51~ (2022)
- Pimentel-Nunes P, "A multicenter prospective study of the real-time use of narrow-band imaging in the diagnosis of premalignant gastric conditions and lesions", Endoscopy, 48, pp.723~730 (2016)
- Pimentel-Nunes P, "White flat lesions in the gastric corpus may be intestinal metaplasia", Endoscopy, 49, pp.617~618 (2017)
- Uedo N, "Multiple white flat lesions in the gastric corpus are not intestinal metaplasia", Endoscopy, 49, pp.615~616 (2017)
- Kumar KR, "Helicobacter gastritis induces changes in the oxyntic mucosa indistinguishable from the effects of proton pump inhibitors", Hum Pathol, 44, pp.2706~2710 (2013)
- Declich P, "Parietal cell hyperplasia with deep cystic dilations : a lesion closely mimicking fundic gland polyps", Am J Gastroenterol, 95, pp.566~568 (2000)